Sanofi entered into an exclusive agreement with Pune-based Emcure Pharmaceuticals for the distribution and promotion of its cardiovascular product portfolio in India. This strategic partnership aims to leverage the strengths of both companies to enhance access to Sanofi’s well-established cardiovascular brands across the country.
Under the terms of the agreement, Emcure Pharmaceuticals will be responsible for the exclusive distribution and promotion of Sanofir cardiovascular range, which includes prominent brands such as Cardace, Clexane, Targocid, Lasix, and Lasilactone. These products are widely recognized and prescribed for various cardiovascular conditions.
While Sanofi India Limited will continue to own, import, and manufacture these branded cardiovascular medications across its facilities in India and internationally, Emcure Pharmaceuticals will leverage its extensive nationwide presence and expertise to engage with healthcare professionals and expand the reach of these therapeutic solutions to patients in need across all regions of India.
Rodolfo Hrosz, managing director of Sanofi India, expressed confidence in the partnership, stating that Emcure’s wide presence across India will benefit both healthcare professionals and patients by creating opportunities to maximize the reach of Sanofi’s cardiovascular products. This collaboration aims to ensure that these essential medications are readily available and accessible to patients throughout the country.
